Interview of David L Porter, MD


Interview of David L Porter, MD
In this interview originally conducted for our Hematologic Oncology Update series, Dr David L Porter gave his perspectives on the exciting work that his group at the University of Pennsylvania and others have been doing with chimeric antigen receptor modified T-cell therapy in chronic lymphocytic leukemia and other hematologic and solid tumors.
 

David L Porter, MD
Abramson Cancer Center
University of Pennsylvania Health System
Jodi Fisher Horowitz Professor of
Leukemia Care Excellence
Director, Blood and Marrow Transplantation
Philadelphia, Pennsylvania

Track 1: Basic principles of chimeric antigen receptor (CAR)-directed therapy
Track 2: Early study results with CAR-modified T cells in chronic lymphocytic leukemia (CLL)
Track 3: Cytokine release syndrome with CAR-engineered T cells
Track 4: Rapid resolution of cytokine release syndrome with the IL-6 antagonist tocilizumab
Track 5: CAR-modified T cells directed against CD19 have long-term persistence and induce durable responses in relapsed/refractory CLL
Track 6: Responses to CAR-directed therapy targeting CD19 in relapsed/refractory acute lymphoblastic leukemia and other hematologic and solid tumors
Track 7: Logistics of CAR-directed therapy
Track 8: Forecast on the future role of CAR-directed therapy and other novel approaches
Track 9: Potential synergy of T-cell-directed therapy with lenalidomide
Track 10: Personal reflections on clinical experiences with first-in-human trials of CAR-directed therapy